SRC Inhibition as a Potential Target for Parkinson's Disease Psychosis

Phase

Condition

Schizotypal Personality Disorder (Spd)

Schizophrenia And Schizoaffective Disorders (Pediatric)

Treatment

N/A

Clinical Study ID

NCT03661125

247303

Ages > 40
All Genders

Study Summary

Parkinson's disease is often characterised by movement symptoms such as rigidity and bradykinesia, however, there are a number of non-motor symptoms that can have a significant impact on quality of life. One of the most common non-motor symptoms of Parkinson's disease is visual hallucinations (where someone sees things that don't exist outside their mind). . Recent findings led to the approval of a drug called Pimavanserin as a treatment for PD psychosis in the USA. Based on other recent studies, we believe that Saracatinib, a drug that interacts within the same system as Pimavanserin, is a potential treatment for PD psychosis. Saracatinib has shown to reduce the intensity of the psychedelic effect induced by psilocybin (a naturally occurring psychedelic found in psilocybe mushrooms) and attenuate social cognition and brain changes in healthy volunteers. The aim of this study is to test the effects of 14 days dosing of saracatinib or placebo on 30 volunteers with PD psychosis. We aim to to use neuroimaging combined with psychopharmacology to provide evidence that a putative new treatment approach can modulate abnormal visual cortex activation in patients with PD psychosis. If positive, this proof of mechanism study would provide a strong platform to pursue symptom modification studies with Saracatinib.

Eligibility Criteria

Inclusion

Inclusion Criteria:

Understand the study procedures and agree to participate by providing written informedconsent.
Have a confirmed diagnosis of Parkinson's disease using internationally accepted UKbrain bank criteria.
Be male or female
Be right handed
Aged 40 years or over
Be judged to be in good health by the investigator, based on clinical evaluationsincluding laboratory safety tests, medical history, physical examination, 12 lead ECGand vital signs measurements performed at screening and prior to administration of theinitial dose of study drug.
Have a score of at least 22 on the Montreal Cognitive Assessment (MoCA).
Have a diagnosis of idiopathic PD with moderate severity
Have a combined score of at least 6 or an individual score of at least 4 on theneuropsychiatric inventory (NPI [20]) 23 items A (delusions) and/or B (hallucinations).

Exclusion

Exclusion Criteria:

Is a female of child bearing potential
Is currently taking anticholinergic medication
Is currently taking any medication known to be a moderate or potent CYP3A4 inducer orinhibitor.
Has an ongoing disability, medical or neurological history, cognitive impairment, orconditions that in the opinion of the investigator may interfere with study conduct orclinical assessments.
Refuses to be withdrawn from quetiapine (see section 4.7).
Has a family history of psychosis in a first degree relative
Has poor peripheral arterial/venous access or recent wrist trauma that will restrictability to gain venous access.
Is currently using prescription or non-prescription drugs and herbal supplements,which are deemed to affect the integrity of the study, within 7 days or 5 half-lives (whichever is longer) prior to the first dose of trial medication. As an exception,paracetamol or acetaminophen may be used at doses of 1 g/day.
Has a history of sensitivity to any of the study medications or any of the excipientconstituents.
Has a history of febrile illness within 5 days prior to the first dose
Has a hairstyle which would affect EEG recording.
Has any condition possibly affecting drug absorption (eg, gastrectomy).
Has a history of regular alcohol consumption exceeding 14 units/week (6 glasses of 13.0% wine (175ml), 6 pints of 4.0% lager or ale (568ml), 5 pints of 4.5% cider (568ml) or 14 glasses of 10.0% spirits (25ml)) within 6 months of screening.
Uses tobacco- or nicotine-containing products in excess of the equivalent of 5cigarettes per day.
Uses caffeine containing products of the equivalence of 5 cups of regular filtercoffee per day
Has a positive urine drug screen on or after the screening visit during their activeinvolvement in the study for opiates, methadone, cocaine, amphetamines (includingMDMA), barbiturates, benzodiazepines and cannabinoids.
Is unwilling or unable to comply with the Lifestyle guidelines.
Has, in the opinion of the investigator, has any medical or psychological condition orsocial circumstances which would impair their ability to participate reliably in thestudy, or who may increase the risk to themselves or others by participating.
Is male and is unwilling to follow the contraception guidance or has a female partnerof child bearing potential who is unwilling to follow the contraception guidancethroughout the study.
Serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2.5 x upperlimit of normal (ULN)
Total bilirubin > 1.25 x ULN
Known congenital long QT syndrome
Baseline resting QTcF > 470ms on 12 lead ECG
Positive hepatitis C antibody, hepatitis B virus surface antigen or hepatitis B viruscore antibody at screening
Known to have tested positive for human immunodeficiency virus.
Participation in another clinical study with an investigational product administeredin the last 3 months
Below the lower limit of normal Hb, total WBC and neutrophils on blood counts as perthe reference ranges of the laboratory conducting the tests.

Study Design

April 11, 2019

September 01, 2021

Study Description

Parkinson's disease (PD) is a neurodegenerative condition which has a 1% prevalence in the over 60s and also affects young adults. As well as motor symptoms such as akinesia or rigidity, many patients also experience non-motor symptoms of which psychosis is the most common (Chang and Fox, 2016). Current treatments for Parkinson's disease psychosis include atypical antipsychotics such as quetiapine, clozapine and pimavanserin (a 5-HT2a inverse agonist). Pimavanserin has recently been approved in the USA as a PD psychosis treatment; it has been shown to have an overall effect on reducing hallucinations as a whole, but not on visual hallucinations specifically. Functional neuroimaging evidence confirms dysfunctional ventral visual pathway activity in PD psychosis with altered metabolism, blood flow and brain activation following visual stimulation (Chang and Fox, 2016). Outside of the ventral visual pathways, two imaging studies in PD patients with visual hallucinations have shown altered connectivity within the default mode network, a brain system implicated in many neuropsychiatric conditions, pointing to more widespread abnormalities (Chang and Fox, 2016). Structural imaging studies show some atrophy within the ventral visual pathways, but also implicates brain regions outside of visual processing areas, including parietal, frontal, and cerebellar and hippocampal regions (Ffytche et al., 2017). Moreover, even though the serotoninergic dysfunction underpinning Parkinson's disease psychosis is not fully understood, animal studies with psychedelics have pointed to the dimerisation of the 5-HT2A and mGlu2 receptors and the over recruitment of specific downstream signalling pathways. Src kinase inhibition is a potential mechanism for blocking the hallucinogenic effects of 5-HT2A receptor agonism. Src kinase inhibitor, Saracatinib, has shown to reduce the intensity of the psychedelic effect induced by psilocybin (a naturally occurring psychedelic found in psilocybe mushrooms (Byock, 2018)) and attenuate social cognition and brain changes in healthy volunteers. We will test the effects of Saracatinib on brain activity associated with visual processing using a visual processing task, known to be sensitive to 5-HT2a receptor stimulation in previous studies with psilocybin (Carter et al., 2004), and a visual recognition task (Meppelink et al., 2009) with known sensitivity to PD psychosis, both scanned using the latest implementation of multi-echo blood oxygen level dependent (BOLD) functional Magnetic Resonance Imaging (fMRI). We aim to conduct a double-blind crossover design study, looking at the effects of Saracatinib and placebo treatment on 26 patients who have PD with psychosis. Existing data shows that 10 days of dosing with Saracatinib will achieve a steady state level that is known to be well tolerated in people with Alzheimer's disease (Nygaard et al., 2015). Therefore, participants will be given an oral dose of 100mg of Saracatinib or placebo as two 50mg tablets to be taken once daily for 14 days. Participants will return to the clinic on day 14 for their final dose of Saracatinib or placebo, fMRI and EEG scans, cognitive assessments, physical examination and blood screen. The participants will then move onto the second treatment arm where they will receive a further 14 days of dosing with saracatinib or placebo depending on the group they were in for the first treatment arm. There will be a minimum 2-week washout between treatment arms to avoid potential carry over effects.

Connect with a study center

Mitul Mehta
London, Camberwell SE5 8AF
United Kingdom
Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.